-+ 0.00%
-+ 0.00%
-+ 0.00%

Colon Pharmaceutical announced that its holding subsidiary, Sichuan Colun Botai Biomedical Co., Ltd., has received a clinical trial notice from the Drug Evaluation Center of the State Drug Administration approving the clinical trial application of the novel dual-load ADC drug SKB565 for the treatment of advanced solid tumors. This is the first clinically-advanced dual-load antibody conjugate drug from Colombotte.

Zhitongcaijing·07/27/2026 11:09:14
Listen to the news
Colon Pharmaceutical announced that its holding subsidiary, Sichuan Colun Botai Biomedical Co., Ltd., has received a clinical trial notice from the Drug Evaluation Center of the State Drug Administration approving the clinical trial application of the novel dual-load ADC drug SKB565 for the treatment of advanced solid tumors. This is the first clinically-advanced dual-load antibody conjugate drug from Colombotte.